<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>3(1)</volume><submitter>van de Lest NA</submitter><pubmed_abstract>&lt;h4>Introduction&lt;/h4>Minimal change disease is a common cause of nephrotic syndrome. In general, patients with minimal change disease respond to corticosteroids and have excellent long-term renal survival. However, some patients have less favorable outcome. These patients are often thought to have progressed to focal segmental glomerulosclerosis. We previously reported that a segmental loss of podocyte markers is present before the development of focal segmental glomerulosclerosis in a rat model. Here, we investigated whether loss of podocyte marker nephrin can serve as a biomarker for predicting poor outcome in patients with minimal change disease.&lt;h4>Methods&lt;/h4>We obtained 47 kidney biopsy samples from patients diagnosed with minimal change disease and stained sections with periodic aci</pubmed_abstract><journal>Kidney international reports</journal><pagination>168-177</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC5762955</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Nephrin Loss Can Be Used to Predict Remission and Long-term Renal Outcome in Patients With Minimal Change Disease.</pubmed_title><pmcid>PMC5762955</pmcid><pubmed_authors>IJpelaar DHT</pubmed_authors><pubmed_authors>Wolterbeek R</pubmed_authors><pubmed_authors>Scharpfenecker M</pubmed_authors><pubmed_authors>Bruijn JA</pubmed_authors><pubmed_authors>Bajema IM</pubmed_authors><pubmed_authors>van de Lest NA</pubmed_authors><pubmed_authors>Zandbergen M</pubmed_authors></additional><is_claimable>false</is_claimable><name>Nephrin Loss Can Be Used to Predict Remission and Long-term Renal Outcome in Patients With Minimal Change Disease.</name><description>&lt;h4>Introduction&lt;/h4>Minimal change disease is a common cause of nephrotic syndrome. In general, patients with minimal change disease respond to corticosteroids and have excellent long-term renal survival. However, some patients have less favorable outcome. These patients are often thought to have progressed to focal segmental glomerulosclerosis. We previously reported that a segmental loss of podocyte markers is present before the development of focal segmental glomerulosclerosis in a rat model. Here, we investigated whether loss of podocyte marker nephrin can serve as a biomarker for predicting poor outcome in patients with minimal change disease.&lt;h4>Methods&lt;/h4>We obtained 47 kidney biopsy samples from patients diagnosed with minimal change disease and stained sections with periodic aci</description><dates><release>2018-01-01T00:00:00Z</release><publication>2018 Jan</publication><modification>2025-04-04T20:43:36.144Z</modification><creation>2019-03-27T00:14:49Z</creation></dates><accession>S-EPMC5762955</accession><cross_references><pubmed>29340328</pubmed><doi>10.1016/j.ekir.2017.09.011</doi></cross_references></HashMap>